Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses

Par Bahadur Pun, Ajaz Ahmad Bhat, Teena Mohan, Smita Kulkarni, Ramesh Paranjape, Donthamshetty Nageswara Rao

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The mucosal immune system acts as a first line of defense against infection caused by luminal pathogens. Because HIV is transmitted primarily via mucosal associated tissues, particularly with sexual transmission, understanding antiviral immunity present at these sites is important. As most of the peptide antigens show poor immunogenicity when immunized alone but after incorporating the same peptide antigens along with adjuvant CpG ODN in microparticles has shown enhanced immunogenicity in the murine model. In the present study we have investigated the immunomodulatory effects of two adjuvants, CpG 1826 and CpG 2006 (Class B, Also known as type K) to the four peptide antigens of HIV such as envelope glycoproteins gp41 Leucine Zipper, gp41 fusion domain and gp120-C2 as well as regulatory protein (Nef) in microparticles, exploring nasal route with single immunization schedule. Peptide (s) alone in the microparticles elicited low peptide specific IgG and IgA peak titres in the sera, whereas the inclusion of CpG ODN with peptides in microparticles significantly enhanced peptide specific IgG and IgA peak titres and such responses were sustained for longer durations. Similarly higher SIgA response was achieved in the mucosal washes with CpG encapsulated in microparticles. Such presence of SIgA in washes was further correlated with the presence of secretory component (SC) in the respective washes. Both adjuvants induced excellent peptide specific IgG and IgA immune responses. Thus the overall study highlighted the importance of CpG ODNs as a mucosal adjuvant for weaker peptide antigens and thus can explore for developing peptide based vaccine against HIV. Crown

Original languageEnglish
Pages (from-to)468-477
Number of pages10
JournalInternational Immunopharmacology
Volume9
Issue number4
DOIs
Publication statusPublished - 1 Apr 2009
Externally publishedYes

Fingerprint

HIV Antigens
Intranasal Administration
Mucosal Immunity
Peptides
Immunoglobulin A
Secretory Immunoglobulin A
Immunoglobulin G
Antigens
nef Gene Products
HIV
Immunization Schedule
Secretory Component
Leucine Zippers
Subunit Vaccines
Crowns
Nose
Antiviral Agents
Immune System
Immunity
Glycoproteins

Keywords

  • CpG ODN
  • Microparticles
  • Secretory IgA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. / Pun, Par Bahadur; Bhat, Ajaz Ahmad; Mohan, Teena; Kulkarni, Smita; Paranjape, Ramesh; Rao, Donthamshetty Nageswara.

In: International Immunopharmacology, Vol. 9, No. 4, 01.04.2009, p. 468-477.

Research output: Contribution to journalArticle

Pun, Par Bahadur ; Bhat, Ajaz Ahmad ; Mohan, Teena ; Kulkarni, Smita ; Paranjape, Ramesh ; Rao, Donthamshetty Nageswara. / Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. In: International Immunopharmacology. 2009 ; Vol. 9, No. 4. pp. 468-477.
@article{5c1dff4e61ae41e8b37e05dd9c5f0ba7,
title = "Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses",
abstract = "The mucosal immune system acts as a first line of defense against infection caused by luminal pathogens. Because HIV is transmitted primarily via mucosal associated tissues, particularly with sexual transmission, understanding antiviral immunity present at these sites is important. As most of the peptide antigens show poor immunogenicity when immunized alone but after incorporating the same peptide antigens along with adjuvant CpG ODN in microparticles has shown enhanced immunogenicity in the murine model. In the present study we have investigated the immunomodulatory effects of two adjuvants, CpG 1826 and CpG 2006 (Class B, Also known as type K) to the four peptide antigens of HIV such as envelope glycoproteins gp41 Leucine Zipper, gp41 fusion domain and gp120-C2 as well as regulatory protein (Nef) in microparticles, exploring nasal route with single immunization schedule. Peptide (s) alone in the microparticles elicited low peptide specific IgG and IgA peak titres in the sera, whereas the inclusion of CpG ODN with peptides in microparticles significantly enhanced peptide specific IgG and IgA peak titres and such responses were sustained for longer durations. Similarly higher SIgA response was achieved in the mucosal washes with CpG encapsulated in microparticles. Such presence of SIgA in washes was further correlated with the presence of secretory component (SC) in the respective washes. Both adjuvants induced excellent peptide specific IgG and IgA immune responses. Thus the overall study highlighted the importance of CpG ODNs as a mucosal adjuvant for weaker peptide antigens and thus can explore for developing peptide based vaccine against HIV. Crown",
keywords = "CpG ODN, Microparticles, Secretory IgA",
author = "Pun, {Par Bahadur} and Bhat, {Ajaz Ahmad} and Teena Mohan and Smita Kulkarni and Ramesh Paranjape and Rao, {Donthamshetty Nageswara}",
year = "2009",
month = "4",
day = "1",
doi = "10.1016/j.intimp.2009.01.012",
language = "English",
volume = "9",
pages = "468--477",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses

AU - Pun, Par Bahadur

AU - Bhat, Ajaz Ahmad

AU - Mohan, Teena

AU - Kulkarni, Smita

AU - Paranjape, Ramesh

AU - Rao, Donthamshetty Nageswara

PY - 2009/4/1

Y1 - 2009/4/1

N2 - The mucosal immune system acts as a first line of defense against infection caused by luminal pathogens. Because HIV is transmitted primarily via mucosal associated tissues, particularly with sexual transmission, understanding antiviral immunity present at these sites is important. As most of the peptide antigens show poor immunogenicity when immunized alone but after incorporating the same peptide antigens along with adjuvant CpG ODN in microparticles has shown enhanced immunogenicity in the murine model. In the present study we have investigated the immunomodulatory effects of two adjuvants, CpG 1826 and CpG 2006 (Class B, Also known as type K) to the four peptide antigens of HIV such as envelope glycoproteins gp41 Leucine Zipper, gp41 fusion domain and gp120-C2 as well as regulatory protein (Nef) in microparticles, exploring nasal route with single immunization schedule. Peptide (s) alone in the microparticles elicited low peptide specific IgG and IgA peak titres in the sera, whereas the inclusion of CpG ODN with peptides in microparticles significantly enhanced peptide specific IgG and IgA peak titres and such responses were sustained for longer durations. Similarly higher SIgA response was achieved in the mucosal washes with CpG encapsulated in microparticles. Such presence of SIgA in washes was further correlated with the presence of secretory component (SC) in the respective washes. Both adjuvants induced excellent peptide specific IgG and IgA immune responses. Thus the overall study highlighted the importance of CpG ODNs as a mucosal adjuvant for weaker peptide antigens and thus can explore for developing peptide based vaccine against HIV. Crown

AB - The mucosal immune system acts as a first line of defense against infection caused by luminal pathogens. Because HIV is transmitted primarily via mucosal associated tissues, particularly with sexual transmission, understanding antiviral immunity present at these sites is important. As most of the peptide antigens show poor immunogenicity when immunized alone but after incorporating the same peptide antigens along with adjuvant CpG ODN in microparticles has shown enhanced immunogenicity in the murine model. In the present study we have investigated the immunomodulatory effects of two adjuvants, CpG 1826 and CpG 2006 (Class B, Also known as type K) to the four peptide antigens of HIV such as envelope glycoproteins gp41 Leucine Zipper, gp41 fusion domain and gp120-C2 as well as regulatory protein (Nef) in microparticles, exploring nasal route with single immunization schedule. Peptide (s) alone in the microparticles elicited low peptide specific IgG and IgA peak titres in the sera, whereas the inclusion of CpG ODN with peptides in microparticles significantly enhanced peptide specific IgG and IgA peak titres and such responses were sustained for longer durations. Similarly higher SIgA response was achieved in the mucosal washes with CpG encapsulated in microparticles. Such presence of SIgA in washes was further correlated with the presence of secretory component (SC) in the respective washes. Both adjuvants induced excellent peptide specific IgG and IgA immune responses. Thus the overall study highlighted the importance of CpG ODNs as a mucosal adjuvant for weaker peptide antigens and thus can explore for developing peptide based vaccine against HIV. Crown

KW - CpG ODN

KW - Microparticles

KW - Secretory IgA

UR - http://www.scopus.com/inward/record.url?scp=61649116885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649116885&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2009.01.012

DO - 10.1016/j.intimp.2009.01.012

M3 - Article

C2 - 19291836

AN - SCOPUS:61649116885

VL - 9

SP - 468

EP - 477

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 4

ER -